Evolus, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.evolus.com

Moat Score
Safety Score

Market Cap $753.84M
PE -14
Debt $125.00M
Cash $85.04M
EV $793.80M
FCF -$23.24M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$55.46M
EBIT	-$40.73M
ROE	-942%
ROA	-18%
FCF	-$23.24M
Equity	$5.89M
Growth Stability	1
PE	-13.59
PB	127.99
P/FCF	-32.44
P/S	3.04
Price/Cash	0.11
Debt/Equity	21.22
Debt/FCF	-5.38
Net Margins	-23%
Gross Margins	70%
Op. Margins	-16%
Sales Growth YoY	22%
Sales Growth QoQ	-9%
Sales CAGR	64%
Equity CAGR	-11%
Earnings Growth YoY	13%

Earnings Growth QoQ	69%
Sales CAGR 5Y	50%
Equity CAGR 5Y	-20%
Earnings CAGR 3Y	36%
Sales CAGR 3Y	36%
Equity CAGR 3Y	-35%
Market Cap	$753.84M
Revenue	$248.33M
Assets	$229.61M
Total Debt	$125.00M
Cash	$85.04M
Shares Outstanding	61.56M
EV	793.8M
Moat Score	2%
Safety Score	48%
Working Capital	89.55M
Current Ratio	2.47
Gross Profit	$173.69M
Shares Growth 3y	5%
Equity Growth QoQ	-70%
Equity Growth YoY	-130%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance.

SEC Filings

Direct access to Evolus, Inc. (EOLS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Evolus, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Evolus, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Evolus, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Evolus, Inc..

Years

Calculation mode

= -$232M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$23M	-$23M	-$23M	-$23M	-$23M	-$23M	-$23M	-$23M	-$23M	-$23M	-$23M	-$232M
DCF		-$21M	-$19M	-$17M	-$16M	-$14M	-$13M	-$12M	-$11M	-$9.9M	-$9M	-$90M
Value	-$232M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-258%	-288%	-47%	-50%	-31%	-23%
ROA	-	-27%	-41%	-73%	-17%	-37%	-26%	-18%
ROE	-	-56%	-113%	223%	-57%	-402%	298%	-942%

Bad Net Margins (-23.29%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0	-0.8	-0.69	-2.22	-0.87	-3.63	-5.38
Debt over Equity	-1.84	0	0.94	-0.56	0.92	4.05	-6.04	21.22
Growth Stability	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-5.38)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Bad Debt/Equity ratio (21.22)

The company is overleveraged and has a bad balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	62%	76%	49%	36%	50%
Earnings YoY growth	-	946%	92%	81%	-71%	59%	-17%	-
Equity YoY growth	-	-212%	-6%	-192%	-212%	-77%	-212%	-20%
FCF YoY growth	-	94%	265%	-37%	-42%	156%	-60%	-